Hoth Therapeutics, Inc. 8-K

What Happened Hoth Therapeutics, Inc. filed a Current Report on Form 8-K on January 16, 2026, disclosing that management prepared presentation materials the company will use in meetings with U.S. government officials regarding its weight‑loss drug and broader therapeutics pipeline. The Presentation Materials are included as Exhibit 99.1 to the 8-K and are described as summary information that should be considered alongside the company’s SEC filings and other public announcements.

Key Details

• Presentation Materials filed as Exhibit 99.1 to the Form 8-K dated January 16, 2026.
• Materials are intended for use “from time to time on and after January 16, 2026” in meetings with U.S. government officials.
• Company states the materials are summary information and speaks as of the 8-K date; it disclaims any obligation to update them.
• The materials cover the company’s weight‑loss drug and its therapeutics pipeline (no financial results or new clinical data were reported in the filing).

Why It Matters This filing signals Hoth’s active engagement with U.S. government stakeholders regarding its lead programs, which can be relevant for regulatory, policy, funding, or collaboration discussions. For investors, the Exhibit 99.1 presentation may provide a concise view of the company’s strategy and program priorities, but it is not a substitute for formal SEC filings or press releases and does not include new financial or clinical outcome disclosures. Review Exhibit 99.1 and the company’s other filings for full context.